Stephen Hill's most recent trade in Avalonbay Communities Inc. was a trade of 1,082 Common Stock, par value $.01 per share done . Disclosure was reported to the exchange on May 28, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avalonbay Communities | Stephen P. Hills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2026 | 1,082 | 10,184 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 18.92 per share. | 11 May 2026 | 89 | 17,894 | - | 18.9 | 1,684 | Common Stock |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 23.39 per share. | 11 Feb 2026 | 1,236 | 17,795 | - | 23.4 | 28,910 | Common Stock |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 65,000 | 65,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 4,000 | 19,140 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 23.12 per share. | 09 Feb 2026 | 109 | 19,031 | - | 23.1 | 2,520 | Common Stock |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 16.12 per share. | 10 Nov 2025 | 95 | 15,750 | - | 16.1 | 1,531 | Common Stock |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 75,000 | 75,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2025 | 8,000 | 16,849 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 10.54 per share. | 20 Aug 2025 | 1,004 | 15,845 | - | 10.5 | 10,586 | Common Stock |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 10.34 per share. | 11 Aug 2025 | 94 | 8,849 | - | 10.3 | 972 | Common Stock |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 10.53 per share. | 11 Aug 2025 | 91 | 8,943 | - | 10.5 | 958 | Common Stock |
| Avalonbay Communities | Stephen P. Hills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 971 | 8,780 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 450,000 | 450,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Hill Stephen | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 112,500 | 172,899 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Hill Stephen | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 56,250 | 56,250 | - | - | Option (right to buy) | |
| Avalonbay Communities | Stephen P. Hills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 980 | 7,576 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 40,000 | 48,928 | - | 0 | Common Stock | |
| Avalonbay Communities | Stephen P. Hills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 990 | 6,380 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Technical Ops. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 900,000 | 900,000 | - | - | Option (right to buy) | |
| Avalonbay Communities | Stephen P. Hills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 852 | 5,217 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lyell Immunopharma Inc | Stephen Hill | Chief Technical Ops. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2022 | 700,000 | 700,000 | - | - | Option (right to buy) |